Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey

(2016) Ruben Mesa et al.   BMC CANCER

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

(2016) Julia Asp et al.   HAEMATOLOGICA

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

(2016) C N Harrison et al.   LEUKEMIA

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

(2016) Julia Asp et al.   HAEMATOLOGICA

The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

(2015) M. Deininger et al.   BLOOD

Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

(2015) Ruben A. Mesa et al.   Clinical Lymphoma Myeloma & Leukemia

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

(2015) P Guglielmelli et al.   Blood Cancer Journal

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

(2014) A. Tefferi et al.   BLOOD

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

(2013) Srdan Verstovsek et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

(2013) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

(2013) Ruben A Mesa et al.   Journal of Hematology & Oncology

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

(2012) V. Gupta et al.   BLOOD

Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study

(2012) Malin Hultcrantz et al.   JOURNAL OF CLINICAL ONCOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients

(2011) A Pardanani et al.   LEUKEMIA

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD